What is Ataxia Market?
Ataxia is a degenerative disease of the nervous system that involves a lack of muscle control or coordination of voluntary movements, such as walking or picking up objects. This condition affects a personís speech, eye movements, and ability to swallow, walk, and pick up objects, among other voluntary movements. This condition in some people is due to genetic factors and in some people can result due to another condition, such as a stroke, MS, a brain tumor, or a head injury, or even from excessive alcohol consumption.
The market study is being classified by Type (Cerebellar Ataxia, Sensory Ataxia and Vestibular Ataxia) and major geographies with country level break-up.
Pfizer, Inc. (United States), Acorda Therapeutics, Inc. (United States), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Forest Laboratories (United States), H. Lundbeck A/S (Denmark), Johnson & Johnson (United States), Merck & Co., Inc. (United States) and Sanofi S.A. (France) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Ataxia market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Ataxia market by Type, Application and Region.
On the basis of geography, the market of Ataxia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Diagnosis Rate of Ataxia due Rise in Number of Diagnostic Centres and Hospitals
- Increasing Awareness about Ataxia among People
- Technological Advancements in Medical Science
- Increased Research and Development Activities
- No Single Product Approval for Ataxia Treatment
- Growing Demand for Proper Cure for Ataxia
- Growth in the Healthcare Industry Worldwide
- Recent Expiry of Certain Drugs that Treat Symptomatic Ataxia
In July 2019, REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, has announced it entered into a license agreement with Pfizer Inc.
Key Target AudienceAtaxia Treatment Providers, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase